T cell News
-
OncoImmunity will start collaborating with a US-based neoantigen specific T-cell therapy company
OncoImmunity announced today the signing of a collaboration agreement with a T cell therapy company based in the US . The companies will cooperate to access the predictive capabilities of OncoImmunity's artificial intelligence platform called the Immuneoprofiler™ to identify immunogenic neoantigens for the US partner’s T-cell platform. The collaboration agreement marks the increasing ...
-
Vicinivax Announces Last Patient Out In The Phase I Study With Immunotherapy Vvax001 ...
ViciniVax is pleased to report today that the last patient has completed treatment in the Phase I study with Vvax001. This study was designed to assess the safety and HPV16 E6,7-specific T-cell immune responses upon injection of 4 different doses of Vvax001 in a total of 12 subjects. Full analysis of the data is expected in Q2 2018. ...
By ViciniVax BV
-
SQZ Biotechnologies Publishes Comprehensive Preclinical Research on SQZ® TAC Platform’s Ability to Induce Multiple Key Mechanisms of AntigenSpecic Tolerance and Protect Against Type 1 Diabetes
WATERTOWN, Mass.--(BUSINESS WIRE)-- SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced the publication of comprehensive preclinical research on the SQZ® Tolerizing Antigen Carrier (TAC) platform. The data, published in Frontiers in Immunology, demonstrated that TACs can induce multiple key mechanisms of ...
-
IN8bio Announces Closing of Exercise Option to Purchase Additional Shares in Public Offering
NEW YORK, Aug. 19, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced that the underwriter of its previously announced underwritten public offering of common stock which closed on August 16, 2022 has partially exercised ...
By IN8Bio Inc.
-
Cabaletta Bio Announces Appointment of Michael Gerard as General Counsel
PHILADELPHIA, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Michael Gerard has been appointed general counsel. ...
-
Adicet Bio to Host Webcast Presentation of ADI-001 Interim Clinical Data in B Cell Non-Hodgkin’s Lymphoma
MENLO PARK, Calif. and BOSTON, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that the Company will host a webcast presentation on Monday, December 6, 2021 at 8:30 AM EST to discuss interim data from its dose escalation Phase ...
By Adicet Bio
-
NexImmune Announces Formation of Autoimmune and Infectious Diseases Scientific Advisory Board
GAITHERSBURG, Md., Jan. 05, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced the formation of its Autoimmune and Infectious Disease Scientific Advisory Board (AI & ID SAB). The AI ...
-
ViciniVax announces first patient treated in Phase I study with immunotherapy Vvax001 for HPV-related precancers and cancer
ViciniVax is pleased to report today that the last patient has completed treatment in the Phase I study with Vvax001. This study was designed to assess the safety and HPV16 E6,7-specific T-cell immune responses upon injection of 4 different doses of Vvax001 in a total of 12 subjects. Full analysis of the data is expected in Q2 2018. ...
By ViciniVax BV
-
Carina Biotech inaugural symposium to be held on 18 May 2022 in Adelaide and virtually
Please Join Us on Wednesday, 18 May 2022 9:30 am – 5:00 pm for Carina Biotech’s inaugural symposium Join us in Adelaide at the Hotel Grand Chancellor and virtually for Carina Biotech’s inaugural symposium showcasing our LGR5 CAR-T programand path to the clinic. Also hear from invited guests in the CAR-T cell therapy field who will share their latest research. RSVP to ...
-
AlloVir to Present at the 40th Annual J.P. Morgan Healthcare Conference
AlloVir (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, at 4:30 p.m. ET. An audio-only webcast of the presentation will be available on the Investors & Press section of the AlloVir website at. An ...
By AlloVir
-
Nanobodies and CAR-T
Researchers from Boston Children’s Hospital and MIT took mini-antibodies from alpacas Bryson and Sanchez. Then they shrunk the mini-antibodies into even smaller nanobodies and engineered these nanobodies onto CAR-T cells. During this process, they discovered a new form of cell therapy. The goal is to enhance CAR-T cells’ targeting abilities by targeting immunosuppressive proteins in ...
By IMAPAC
-
CGTLive Interview: New Frontiers in Allogeneic Cell Therapy
Cartherics’ CEO, Professor Alan Trounson, was recently interviewed by CGTLive, to discuss the company’s development of NK cell, T-cell and macrophage cell therapies for various solid tumours. Cartherics is using its induced pluripotent stem (iPS) cell platform to develop NK cell, T-cell, and macrophage cell therapies with potential indications for solid tumour types including ...
-
AlloVir to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
AlloVir (Nasdaq: ALVR), a late clinical-stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 10:00 a.m. EST. A live webcast of the fireside chat will be available on the Investors & Press section of the AlloVir ...
By AlloVir
-
Cabaletta Bio Reports Top-line Biologic Activity Data from Two Lowest Dose Cohorts in DesCAARTes™ Trial in Patients with Mucosal Pemphigus Vulgaris
PHILADELPHIA, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today reported top-line data on biologic activity from the two lowest dose cohorts in the DesCAARTes™ Phase 1 clinical trial of DSG3-CAART for ...
-
Celyad Oncology to Present at the H.C. Wainwright Global Investment Conference
Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company plans to participate virtually at the upcoming H.C. Wainwright Global Investment Conference, May 23 ...
-
Valo Health Announces Publication of the Journal of Clinical Investigation of a New Therapeutic Approach to Improve CD8+ T Cell Function
Valo Health, Inc (“Valo”), the technology company focused on transforming the drug discovery and development process using human-centric data and artificial intelligence, announced a proof of concept for using its preclinical asset, OPL-0101, to target CD8+ T cells, in the ...
-
NexImmune Announces Preliminary Phase 1/2 NEXI-002 Results in Patients with Multiple Myeloma
GAITHERSBURG, Md., Dec. 12, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced preliminary Phase 1/2 results from an ongoing study of NEXI-002, a patient-derived multi-antigen-specific ...
-
Peter MacCallum Cancer Centre and Cartherics Announce Collaboration to Develop Autologous CAR-T Cell Therapy for Cutaneous T-Cell Lymphoma
The Peter MacCallum Cancer Centre (“Peter Mac”) and Cartherics Pty Ltd (“Cartherics”) announced today they have entered into a Collaborative Development Program Agreement (CDPA) to develop Cartherics’ proprietary autologous CAR-T cell therapy (CTH-001) for the treatment of cutaneous T-cell lymphoma (CTCL). “Patients with advanced stages of cutaneous T-cell ...
-
CellFE platform enables microfluidic Transfection of mRNA into T cells and HSPCs
CellFE Biotech, a microfluidics-based biotech startup based out of Alameda, CA, has recently had an article published in Scientific Reports. The article, cited below, focuses on the use of a novel microfluidics platform to successfully achieve the transfection of mRNA into T-cells, particularly through volume exchange for convective transfection (VECT). The delivery of mRNA offers a distinct ...
By CellFE
-
Carina Biotech raises $7.5 million at first close with Tenmile as the cornerstone investor
Carina Biotech is extremely pleased to announce that it has raised $7.5 million at first close of its current funding round, welcoming on board new venture capital business Tenmile as the cornerstone investor together with strong support from existing investors. “We are delighted to welcome Tenmile as an investor in Carina Biotech with its commitment to accelerate high impact, cutting edge ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you